Objective: The purpose of this study was to evaluate the utility of core needle biopsy as a diagnostic tool for palpable breast lumps in developing countries as compared to fine needle aspiration cytology .
INTRODuCTION
Breast carcinoma is one of the leading causes of cancer in women worldwide both in developed and developing countries. Due to lack of breast screening practices in developing nations, patients present with palpable breast lumps. Studies regarding the comparison of core needle biopsy (CNB) and fine needle aspiration cytology (FNaC) in palpable breast lumps within the same patient population are relatively scarce whereas those of screen-detected breast lesions are plenty. We therefore decided to evaluate the utility of CNB as a routine diagnostic procedure for palpable breast lumps as compared to FNaC.
MATERIAL and METHODS
This prospective study was conducted in a tertiary care hospital over a period of two years. Study subjects were all patients attending the surgery outpatient department (OPD) for breast pathology. a detailed clinical history and examination was done using a standardized proforma. Patients with a positive clinical examination (palpable breast lump/nodularity) were subjected to simultaneous FNaC and CNB by the same surgeon (GT). Patients with palpable axillary lymph nodes were excluded from the study.
after patient selection, FNaC from the lumps was done using the method described by Frable WJ et al. (1) . Both wet fixed in 95% ethanol and air-dried smears were prepared. all cytology smears were stained by May Grunwald Giemsa, Papanicolaou and Hematoxylin & Eosin stains. The average number of FNa passes recommended for adequate sampling of most palpable breast masses was two-four (2) . adequate smears were defined as aspirates containing more than four to six well visualized cell groups. a cell group can be an acinous (cluster of at least 6 cells) or a flat sheet (no fewer than 10 cells) (3).
CNB was performed freehand/unguided on the breast lumps in a single session as FNa with a manual 14 gauge needle (Shoney Cut Biopsy Needle with 20 mm specimen notch) after informed consent and coagulation profile. Core biopsy was performed as per the procedure described (4) . The specimens were fixed in 10% neutral buffered formalin for a minimum of 6 hours as recommended (5) . Typically three to five samples were taken through different parts of the lesion to ensure adequacy of sampling. No more than five needle core biopsies (for a maximum aggregate length of 100 mm) were processed in one block (6) . Whenever possible the cores were arranged in parallel arrays. all of the core needle biopsies were submitted for microscopic examination. at least three histological levels were prepared from each block. additional levels were prepared as required.
The outcomes of FNaC and CNB were reported using the standard National Health Service Breast Screening Programme (NHSBSP) criteria. The diagnoses offered by FNaC and CNB were not accepted blindly and were interpreted in the light of corresponding clinical and radiological findings. Whenever there was a discrepancy in this triple assessment, appropriate action was initiated.
RESuLTS
a total of 107 breast lumps were subjected to simultaneous FNaC and CNB in this study and histopathology was available for 85 cases. The patients ranged in age from 13 to 73 years (average age, 31-50 years). Lesions ranged in size from 1 cm to 15 cm. The palpable lumps had two peaks. Twenty-four cases (22.42%) had lumps of size up to 2 cm while 26 cases (24.29%) had breast lumps more than 5 cm in size. Ninety-eight patients (91.58%) had a single lump in either breast. Nine patients (8.41%) had multiple lumps, out of which 4 patients had multiple lumps in a single breast while 5 patients had lumps in both breasts.
The FNaC and CNB diagnoses for the 107 cases are shown in Table I . Specific diagnoses for the B2 and B5 categories of CNB are presented in Table II. The comparison between FNaC and CNB diagnoses was as follows (Table III) 
CNB and histopathology of C2 (benign) category of FNAC:
Thirty cases were benign (C2) on FNaC. CNB was done in all cases while histopathology was available for 14 cases. Cytology-CNB-Histopathology concordance was seen in eleven cases consisting of fibroadenoma (n=7) and benign phyllodes tumor (n=4). One case diagnosed as inflammatory on FNaC was given a diagnosis of fat (3) uC (1) PC ( necrosis on CNB and histopathology. Two cases were discordant and were diagnosed as benign breast lesion (BBL) and benign phyllodes tumor (BPT) on FNaC but were given a diagnosis of IDC and malignant phyllodes tumor (MPT) on CNB and histopathology. Twelve cases showed cytology-CNB-radiology concordance and thus the lesions were not excised. The remaining four C2 cases showed unsatisfactory material (B1) on CNB. Since the radiology/clinical examination was benign, no further intervention was done.
CNB and histopathology of C3 (Atypia probably benign) category of FNAC:
Thirty-five cases were atypical (C3) on FNaC. CNB was performed for all the 35 cases while histopathology was available for 31 cases. Nineteen cases were classified as benign on CNB (B2) and histopathology. These were diagnosed as fibrocystic change (FCC) (n=9), sclerosing adenosis (n=3), fibroadenoma (n=1), BPT (n=1) and epithelial hyperplasia of usual type (n=4). One case diagnosed as BBL on CNB turned out to be hamartoma on histopathology. Seven cases were given a malignant diagnoses on CNB (B5) and histopathology. Six cases were IDC on CNB, with 2 cases of Grade I, 2 cases of Grade II and 2 cases of Grade III on subsequent histopathology. One case that was given a diagnosis of papillary neoplasm on FNaC was given a diagnosis of papillary carcinoma on CNB and turned out to be intracystic papillary carcinoma on histopathology. One case diagnosed as suspicious for studies (14, 15, 25) . This was also reflected in the statistical analysis using McNemars Chi-square test where there was a concordance between the diagnoses offered by CNB and histopathology, whereas any discordance between FNaC and histopathology diagnoses was quite apparent.
CNB detected more breast carcinomas as compared to FNaC in this study with a sensitivity of 95.83%, which is comparable to other studies of palpable breast lumps (8,10-13, 15, 26) . The specificity and positive predictive value of CNB was found to be 100%, i.e., the cases that were assigned to B5 (malignant) category in fact proved to be malignant on subsequent histopathology, a finding also observed in other studies of palpable breast lumps (8, 13, 14, 26, 27) .
Typing of breast carcinomas on CNB co-related well with the final histopathological diagnoses in all the cases while grading was not attempted. Other studies have also found typing of breast carcinoma to be more accurate than grading on core biopsy (11, 28) . Thus grading of breast carcinomas is not mandatory on CNB or on FNaC, a view also proposed by a recent review article (29) .
The inadequate rate (category B1) of CNB in this study was 7.47%. This inadequate rate was slightly higher than that seen in the studies of Shannon et al. and Poon and Kocjan who report an inadequate rate of 5% and 2.3% respectively (11, 14) . FCC was the final histopathological diagnosis in half of the cases that were missed on CNB and placed in C3 (atypia probably benign) category of FNaC. Thus the rubbery consistency of the lesions made the CB needle to slip, making procurement of tissue difficult and yielding an inadequate core of tissue. Comparing the inadequate rates of CNB and FNaC by Pearson's Chi square test (p=0.122) showed no statistical difference between CNB and FNaC as far as the number of reported inadequate cases were concerned.
In this era of neoadjuvant therapy and personalised medicine, ancillary immunohistochemical (Er, Pr, cerb2) and molecular tests can be more reliably and easily performed on CNB than on FNaC (23, 30) . CNB is also more robust in distinguishing between invasive lobular and invasive ductal carcinoma, based on histological and immunohistochemical features. This distinction has important clinical implications. also, CNB contains rNa/ DNa in sufficient quantity and quality for molecular testing, which can be difficult to obtain in the case of FNaC which has limited yield.
regarding cost effectiveness, FNaC is fast and therefore must be preferred for some palpable, probably benign surgery since no distinction is possible between infiltrating and non infiltrating lesions and also because certain cases of clinically apparent malignancy require preoperative chemotherapy based on estrogen and progesterone receptor (Er and Pr) and c-erb-B2 status (8, 9) . Percutaneous core needle biopsy (CNB) is an accurate test for sampling breast lesions and is therefore increasingly replacing fine needle aspiration cytology (FNaC) in breast diagnosis.
The sensitivity of FNaC in detecting malignancy was 64.58% in this study, which is similar to other studies of palpable breast lumps in which both FNa and CNB were done (10) (11) (12) (13) (14) (15) . The specificity and positive predictive value of FNaC was found to be 100% i.e., the cases that were assigned to C5 (malignant) category in fact proved to be malignant on subsequent histopathology which is comparable with other studies of palpable breast lumps (13, 15) . However, a significant number of cases (17) were missed/ underdiagnosed on FNaC in this study, which is reflected by the false negative rate of FNaC of 35.41% and a negative predictive value of 68.51%. They were placed in C1 (2 cases), C2 (2 cases), C3 (8 cases) and C4 (5 cases) categories. The cases that were placed in C1 and C2 categories and were later found out to be malignant on CNB were missed on FNaC due to sampling error. One case, that of malignant phyllodes tumor, deserves special mention as it was diagnosed as benign phyllodes tumor on FNaC whereas the malignant change was picked up by CNB. as stated by Jacklin et al., the accuracy of FNaC in the diagnosis of phyllodes tumor of the breast depends on an adequate and representative sample (16) . Sampling problems can arise in phyllodes tumors because of the heterogeneous nature of these tumors which means that the sampling should be thorough to minimize the risk of sampling error, both with FNa and CNB.
CNB was able to correctly categorize C3 and C4 cases into either benign or malignant categories. B3 (Benign, but of uncertain malignant potential) category had only a single case as compared to the C3 category of FNaC that had 35 cases. This implies that the lesions diagnosed as borderline or suspicious (C3, C4) on FNaC should be confirmed by a biopsy, either open biopsy or minimally invasive core biopsy, a view also supported by other authors (11, (17) (18) (19) (20) (21) (22) (23) (24) . Besides, none of the cases placed in the B2 category were found out to be malignant on FNaC/histopathology. also none of the B4 cases had a malignant FNaC diagnosis. Thus FNaC was unable to improve upon any of the diagnoses offered by CNB in any of the categories. On the contrary, CNB improved the preoperative diagnosis more often than did FNaC, a finding also observed in other lesions, staging of breast carcinoma, in particular preoperative axillary lymph node FNaC, and the diagnosis of metastatic disease. In the case of (potential) malignancy, the speed advantage of FNaC over CNB seems irrelevant in view of the required multidisciplinary meeting to arrive at a therapy plan. an interesting study showed that an indefinite diagnosis using FNaC required additional CNB and surgical excision biopsies in 32% and 21% of cases respectively (31 
